<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>6(23)</volume><submitter>Grasso F</submitter><pubmed_abstract>MUTYH DNA glycosylase removes mismatched adenine opposite 7, 8-dihydro-8-oxoguanine (8-oxoG), which is the major mutagenic lesion induced by oxidative stress. Biallelic mutations in MUTYH are associated with MUTYH-Associated polyposis (MAP) and increased risk in colorectal cancer (CRC). We investigated cancer susceptibility associated with MUTYH inactivation in a mouse model of inflammation-dependent carcinogenesis induced by azoxymethane (AOM) and dextran sulphate (DSS). Mutyh-/- mice were more sensitive than wild-type (WT) animals to AOM/DSS toxicity and accumulated DNA 8-oxoG in their gastrointestinal tract. AOM/DSS-induced colonic adenomas were significantly more numerous in Mutyh-/- than in WT animals, and frequently showed a tubulo-villous feature along with high-grade dysplasia and larger size lesions. This condition resulted in a greater propensity to develop adenocarcinomas. The colon of untreated Mutyh-/- mice expressed higher basal levels of pro-inflammatory cytokines GM-CSF and IFNγ, and treatment with AOM/DSS induced an early decrease in circulating CD4+ and CD8+ T lymphocytes and an increase in myeloid-derived suppressor cells (MDSCs). Adenomas from Mutyh-/- mice had a greater infiltrate of Foxp3+ T regulatory cells, granulocytes, macrophages, MDSCs and strong expression of TGF-β-latency-associated peptide and IL6. Our findings indicate that MUTYH loss is associated with an increase in CRC risk, which involves immunosuppression and altered inflammatory response. We propose that the AOM/DSS initiation/promotion protocol in Mutyh-/- mice provides a good model for MAP.</pubmed_abstract><journal>Oncotarget</journal><pagination>19671-84</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4637313</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The MUTYH base excision repair gene protects against inflammation-associated colorectal carcinogenesis.</pubmed_title><pmcid>PMC4637313</pmcid><pubmed_authors>Pasquini L</pubmed_authors><pubmed_authors>Grasso F</pubmed_authors><pubmed_authors>De Luca G</pubmed_authors><pubmed_authors>Di Carlo E</pubmed_authors><pubmed_authors>Biffoni M</pubmed_authors><pubmed_authors>Di Meo S</pubmed_authors><pubmed_authors>Boirivant M</pubmed_authors><pubmed_authors>Rossi S</pubmed_authors><pubmed_authors>Bignami M</pubmed_authors></additional><is_claimable>false</is_claimable><name>The MUTYH base excision repair gene protects against inflammation-associated colorectal carcinogenesis.</name><description>MUTYH DNA glycosylase removes mismatched adenine opposite 7, 8-dihydro-8-oxoguanine (8-oxoG), which is the major mutagenic lesion induced by oxidative stress. Biallelic mutations in MUTYH are associated with MUTYH-Associated polyposis (MAP) and increased risk in colorectal cancer (CRC). We investigated cancer susceptibility associated with MUTYH inactivation in a mouse model of inflammation-dependent carcinogenesis induced by azoxymethane (AOM) and dextran sulphate (DSS). Mutyh-/- mice were more sensitive than wild-type (WT) animals to AOM/DSS toxicity and accumulated DNA 8-oxoG in their gastrointestinal tract. AOM/DSS-induced colonic adenomas were significantly more numerous in Mutyh-/- than in WT animals, and frequently showed a tubulo-villous feature along with high-grade dysplasia and larger size lesions. This condition resulted in a greater propensity to develop adenocarcinomas. The colon of untreated Mutyh-/- mice expressed higher basal levels of pro-inflammatory cytokines GM-CSF and IFNγ, and treatment with AOM/DSS induced an early decrease in circulating CD4+ and CD8+ T lymphocytes and an increase in myeloid-derived suppressor cells (MDSCs). Adenomas from Mutyh-/- mice had a greater infiltrate of Foxp3+ T regulatory cells, granulocytes, macrophages, MDSCs and strong expression of TGF-β-latency-associated peptide and IL6. Our findings indicate that MUTYH loss is associated with an increase in CRC risk, which involves immunosuppression and altered inflammatory response. We propose that the AOM/DSS initiation/promotion protocol in Mutyh-/- mice provides a good model for MAP.</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Aug</publication><modification>2025-04-19T06:26:19.534Z</modification><creation>2019-03-27T02:01:33Z</creation></dates><accession>S-EPMC4637313</accession><cross_references><pubmed>26109431</pubmed><doi>10.18632/oncotarget.4284</doi></cross_references></HashMap>